SG Americas Securities LLC Has $2.67 Million Stock Holdings in argenex SE $ARGX

SG Americas Securities LLC increased its stake in argenex SE (NASDAQ:ARGX) by 94.9% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 3,179 shares of the company’s stock after purchasing an additional 1,548 shares during the period. SG Americas Securities LLC’s holdings in argenex were worth $2,673,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also bought and sold shares of the company. Wellington Management Group LLP increased its holdings in argenex by 80.1% in the 3rd quarter. Wellington Management Group LLP now owns 729,986 shares of the company’s stock valued at $538,408,000 after buying an additional 324,653 shares during the period. Two Sigma Investments LP boosted its position in shares of argenex by 570.3% during the 3rd quarter. Two Sigma Investments LP now owns 294,160 shares of the company’s stock worth $216,961,000 after acquiring an additional 250,278 shares in the last quarter. Adage Capital Partners GP L.L.C. increased its stake in argenex by 114.3% in the second quarter. Adage Capital Partners GP L.L.C. now owns 297,113 shares of the company’s stock valued at $163,775,000 after acquiring an additional 158,476 shares during the last quarter. Woodline Partners LP raised its position in argenex by 320.8% during the third quarter. Woodline Partners LP now owns 169,476 shares of the company’s stock valued at $124,999,000 after purchasing an additional 129,205 shares in the last quarter. Finally, Alkeon Capital Management LLC lifted its stake in argenex by 133.3% during the third quarter. Alkeon Capital Management LLC now owns 175,000 shares of the company’s stock worth $129,073,000 after purchasing an additional 100,000 shares during the last quarter. Institutional investors own 60.32% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts have recently commented on the company. DZ Bank raised argenex to a “strong-buy” rating in a report on Friday, December 19th. Royal Bank Of Canada reduced their price target on shares of argenex from $925.00 to $890.00 and set an “outperform” rating on the stock in a research note on Friday, February 27th. HC Wainwright upped their price objective on shares of argenex from $915.00 to $940.00 and gave the stock a “buy” rating in a research report on Friday, February 27th. Deutsche Bank Aktiengesellschaft raised shares of argenex from a “hold” rating to a “buy” rating in a research note on Tuesday, March 10th. Finally, Citizens Jmp raised their target price on shares of argenex from $925.00 to $944.00 and gave the company a “market outperform” rating in a research report on Friday, February 27th. One equities research analyst has rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and four have issued a Hold rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $1,016.22.

argenex Price Performance

Shares of NASDAQ ARGX opened at $746.42 on Friday. The company has a 50 day simple moving average of $773.10 and a 200 day simple moving average of $812.65. argenex SE has a 1 year low of $510.05 and a 1 year high of $934.62. The firm has a market cap of $46.19 billion, a PE ratio of 38.24, a price-to-earnings-growth ratio of 1.23 and a beta of 0.46.

argenex (NASDAQ:ARGX) last posted its earnings results on Saturday, February 14th. The company reported $8.02 earnings per share for the quarter. argenex had a net margin of 30.42% and a return on equity of 38.51%. As a group, research analysts anticipate that argenex SE will post 3.13 earnings per share for the current fiscal year.

argenex Profile

argenx (NASDAQ: ARGX) is a biotechnology company focused on the discovery, development and commercialization of antibody-based therapeutics for severe autoimmune and neuromuscular diseases. The company uses its proprietary SIMPLE Antibody platform to generate differentiated antibodies and engineered Fc regions, and it pursues mechanisms that modulate the neonatal Fc receptor (FcRn) to reduce pathogenic IgG levels. Argenx’s research and development activities span target identification, preclinical development and late-stage clinical programs aimed at addressing unmet needs in immunology.

The company’s lead product, efgartigimod (marketed as Vyvgart), is an FcRn antagonist developed to reduce circulating IgG antibodies and treat IgG-mediated disorders.